Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 0

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 0
---
#### FORM 6-K
<div align='center'>SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of April 2025

Commission File Number: 001-11960</div>

#### AstraZeneca PLC
<div align='center'>1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________</div>

#### AstraZeneca PLC
<div align='center'>INDEX TO EXHIBITS</div>

#### 1.

#### 1st Quarter Results
**Click on, or paste, the following link into your web browser, to view the associated PDF document.

http://www.rns-pdf.londonstockexchange.com/rns/5152G_1-2025-4-28.pdf

29 April 2025

AstraZeneca results: Q1 2025

Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition

Revenue and EPS summary**

|                       | Q1 2025 | % Change |      |
|                       |      $m |   Actual | CER1 |
| - Product Sales       |  12,875 |        6 |    9 |
| - Alliance Revenue    |     639 |       40 |   42 |
| Product Revenue2      |